Peripheral artery disease (PAD) affects approximately 230 million people worldwide and is associated with an increased risk of major adverse cardiovascular and limb events. Even though this condition is considered a cardiovascular equivalent, it remains an underrecognized and undertreated entity. Antiplatelet and statin therapy, along with smoking cessation, are the foundations of therapy to reduce adverse events but are challenging to fully implement in this patient population. Race and socioeconomic status also have profound impacts on PAD outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mcna.2023.05.007 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!